Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

VILLEJUIF, France–(BUSINESS WIRE)–Regulatory News Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (“Valerio” or the “Company”), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV (“Etherna”) (the “Acquisition”). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to